Deleterious mutations in the tumour suppressor genes BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer [1], [2], and have been implicated in the genetic susceptibility to prostate cancer (PCa). The gene discussed is BRCA2; the disease is prostate cancer.